Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

ncer cells. It is unique because, in contrast to competing agents, TB-403 only blocks blood vessels in tumour tissue and not in healthy tissue. This novel product, which acts on PIGF, is being co-developed with BioInvent International.

TB-403 is attracting growing interest from potential pharma partners based on both the need for improved products for the treatment of cancer and the exciting pre-clinical results which were published in a Cell feature article in the November 2, 2007 issue.(1)

The commercial potential of TB-403 could also be enhanced as TB-403 could also be used to treat a number of important back of the eye diseases. This is because common eye diseases such as age-related macular degeneration and diabetic retinopathy are caused by uncontrolled blood vessel growth, which could be halted using TB-403.

The Remainder of 2008

ThromboGenics expects to deliver a number of value creating clinical milestones during the remainder of 2008. The expected milestones over this period are:

Microplasmin

- Top line results are expected from the MIVI III Phase IIb trial of microplasmin in vitrectomy in June 2008.

ThromboGenics began the MIVI III Phase IIb trial in January 2007. The trial is evaluating the safety and efficacy of microplasmin intravitreal injection seven days prior to vitrectomy. The results from this trial will be presented at the World Ophthalmology Congress in Hong Kong on June 28, 2008.

Based on the results of this trial, ThromboGenics will select the best dose of microplasmin for use in two separate Phase III studies, one US and one European based. These trials, which are designed to clearly demonstrate the efficacy of microplasmin, are expected to begin before the end of 2008.

- Six month results from the MIVI IIT Phase IIa trial of microplasmin in vitreomacular traction are to be presented at the Euretina Conference in May.

The six month results from the first two cohorts of thi
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Pittcon is pleased to announce ... session on chemical spectroscopic imaging at JASIS 2015 (Japan Analytical & Scientific Instruments ... and scientific instruments show which will be held at International Conference Hall in ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City ... firms and animal health companies to hear from animal health companies with the ... also received licensing agreements or distribution contracts. This meeting is one of ...
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... 2015 GlassesOff (OTCBB: GLSO), a visual ... the human vision system, announced today a partnership with eight-time ... Chris Paul to develop a new mobile app designed ... their real-life on-court performance. Vision is the inception ... shooting a ball or blocking a pass. The critical impact ...
Breaking Biology Technology:U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3
... Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ... Parker et al. entitled "Anti-Tumor Activity of Reovirus is ... Irradiation in Primary Patient Glioma Xenografts Resistant to Treatment ... 28th American Society for Virology (ASV) Annual Meeting. The ...
... of 2009 (Excluding Technical, Plastics) at Prior ... - Sales Decline in the Cyclical Segments of Cosmetics and, ... In the first half of 2009, Gerresheimer AG achieved sales at the ... to sales growth for pharmaceutical packaging and systems,with which Gerresheimer today makes ...
... , SAN DIEGO, July 14 Amylin Pharmaceuticals, Inc. ... the second quarter of 2009 on Tuesday, July 21, 2009 at 5:00 p.m. ... lead the call. On the same date post-market, Amylin will release financial results ... The call will be webcast live through Amylin,s corporate Web site ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting 2Gerresheimer Holds its own in Difficult Environment 2Gerresheimer Holds its own in Difficult Environment 3Gerresheimer Holds its own in Difficult Environment 4Amylin Pharmaceuticals to Webcast Second Quarter Results 2
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik ... und findet vom 22. bis 25. Oktober 2015 ... Die Konferenz feiert in diesem ... ist die ICG weltweit zu einem der einflussreichsten ... eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... biochemical variations, or noise, leads to oscillations in gene ... debated for decades the relative importance of nature versus ... and now UCSD scientists report that noise could also ... In a paper in Proceedings of the National Academy ...
... EU-financed sleep research project is coordinated from FinlandIn ... network was establishedto investigate the causes and implications ... as from the social point of view. This ... effects of sleep restriction" will last for four ...
... cells is the work of machines that contain dozens of ... genomes, researchers now have a nearly complete "parts list" of ... all the pieces go. A new study by scientists at ... question for some of the smallest and trickiest components in ...
Cached Biology News:Phenotype is influenced by nature, nurture and noise 2Do the Europeans turn ill sitting up so late? 2Many needles, many haystacks 2
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
Synaptotagmin, phosphoSer309...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Mouse anti-hepatitis delta virus Class: Antibody Product Group: Bacterial and Viral Antigen...
Biology Products: